Our study demonstrates that neoadjuvant chemotherapy combined with trastuzumab and pertuzumab is an effective treatment strategy for locally advanced HER2-positive colon cancer patients, indicating the potential of HER2 targeting in neoadjuvant therapy and highlighting the importance of assessing HER2 status in all colorectal cancer patients. Here, ERBB2 is linked to malignant colon neoplasm.